title: Preliminary studies of the effects of vascular adhesion protein-1 inhibitors on experimental corneal neovascularization.
abstract: Vascular adhesion protein-1 (VAP-1) controls the adhesion of lymphocytes to endothelial cells and is upregulated at sites of inflammation. Moreover, it expresses amine oxidase activity, due to the sequence identity with semicarbazide-sensitive amine oxidase. Recent studies indicate a significant role for VAP-1 in neovascularization, besides its contribution to inflammation. Pathological blood vessel development in severe ocular diseases (such as diabetes, age-related macula degeneration, trauma and infections) might lead to decreased visual acuity and finally to blindness, yet there is no clear consensus as to its appropriate treatment. In the present case study, the effects of two VAP-1 inhibitors on experimentally induced corneal neovascularization in rabbits were compared with the effects of a known inhibitor of angiogenesis, bevacizumab, an anti-vascular endothelial growth factor antibody. In accordance with recent literature data, the results of the preliminary study reported here indicate that the administration of VAP-1 inhibitors is a potentially valuable therapeutic option in the treatment of corneal neovascularization.
authors.affiliation: Department of Ophthalmology, Semmelweis University, Mária u. 39, Budapest, 1085, Hungary.
authors.forename: Anna
authors.initials: A
authors.lastname: Enzsöly
authors.forename: Petra
authors.initials: P
authors.lastname: Dunkel
authors.forename: Zsuzsa
authors.initials: Z
authors.lastname: Récsán
authors.forename: Hajnalka
authors.initials: H
authors.lastname: Gyorffy
authors.forename: Jeanette
authors.initials: J
authors.lastname: Tóth
authors.forename: Gábor
authors.initials: G
authors.lastname: Marics
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Bori
authors.forename: Miklós
authors.initials: M
authors.lastname: Tóth
authors.forename: Romána
authors.initials: R
authors.lastname: Zelkó
authors.forename: Maria Luisa
authors.initials: ML
authors.lastname: Di Paolo
authors.forename: Péter
authors.initials: P
authors.lastname: Mátyus
authors.forename: János
authors.initials: J
authors.lastname: Németh
mesh_terms: D006631:Amine Oxidase (Copper-Containing) / Q000037:antagonists & inhibitors* / Q000502:physiology; D020533:Angiogenesis Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D042501:Angiogenic Proteins / Q000037:antagonists & inhibitors* / Q000502:physiology; D000818:Animals; D015815:Cell Adhesion Molecules / Q000037:antagonists & inhibitors* / Q000502:physiology; D016510:Corneal Neovascularization / Q000188:drug therapy* / Q000201:enzymology; D004195:Disease Models, Animal; D004791:Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D011817:Rabbits
chemical_list: D020533:Angiogenesis Inhibitors; D042501:Angiogenic Proteins; D015815:Cell Adhesion Molecules; D004791:Enzyme Inhibitors; D006631:Amine Oxidase (Copper-Containing)